Patients with non-cystic fibrosis bronchiectasis (NCFBE), a progressive pulmonary disease, currently have no treatment options in the US. Nancy Pecota, CFO of Aradigm Corporation, discusses NCFBE and what Aradigm is doing to help these patients and possibly others who have an un-diagnosed condition . Their inhalable drug Linhaliq™ is currently on the fast track for FDA approval for NCFBE. Nancy discusses Aradigm's progress to provide an effective treatment option and prevent future infections in these patients. #bronchiectasis #NCFBE  #Linhaliq  #Aradigm  #pulmonarydisease Aradigm.com